See more : PCBL Limited (PCBL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Galmed Pharmaceuticals Ltd. (GLMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galmed Pharmaceuticals Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Addsino Co., Ltd. (000547.SZ) Income Statement Analysis – Financial Results
- Cliq Digital AG (CLQDF) Income Statement Analysis – Financial Results
- Immotion Group Plc (IMMO.L) Income Statement Analysis – Financial Results
- Ginwa Enterprise (Group) Inc. (600080.SS) Income Statement Analysis – Financial Results
- Integrated Electronic Systems Lab Co., Ltd. (002339.SZ) Income Statement Analysis – Financial Results
Galmed Pharmaceuticals Ltd. (GLMD)
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.04M | 1.09M | 467.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 31.00K | 35.00K | 42.00K | 39.00K | 35.00K | 0.00 | 0.00 | 0.00 | 50.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -31.00K | -35.00K | -42.00K | -39.00K | -35.00K | 2.04M | 1.09M | 467.00K | -50.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.57M | 13.00M | 27.22M | 26.08M | 18.18M | 8.31M | 9.65M | 14.27M | 7.63M | 6.66M | 7.21M | 2.44M |
| General & Administrative | 3.72M | 4.66M | 5.66M | 4.13M | 4.20M | 4.44M | 3.80M | 3.08M | 3.25M | 2.48M | 7.36M | 694.00K |
| Selling & Marketing | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.92M | 4.66M | 5.66M | 4.13M | 4.20M | 4.44M | 3.80M | 3.08M | 3.25M | 2.48M | 7.36M | 694.00K |
| Other Expenses | -14.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 0.00 |
| Operating Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Cost & Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Interest Income | 375.00K | 297.00K | 562.00K | 1.19M | 1.92M | 959.00K | 65.00K | 35.00K | 253.00K | 40.00K | 0.00 | 6.00 |
| Interest Expense | 11.00K | 215.00K | 43.00K | 31.00K | 33.00K | 42.00K | 49.00K | 67.00K | 0.00 | 0.00 | 34.00K | 0.00 |
| Depreciation & Amortization | 31.00K | 35.00K | 42.00K | 39.00K | 35.00K | 387.00K | 239.00K | 169.00K | 50.00K | 9.00K | 4.00K | 5.00K |
| EBITDA | -6.87M | -17.62M | -32.84M | -30.17M | -22.34M | -10.33M | -12.13M | -16.71M | -10.83M | -9.13M | -14.57M | -3.13K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -507.61% | -1,117.51% | -3,578.80% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 7.49M | -17.65M | -32.88M | -30.21M | -22.38M | -10.72M | -12.36M | -16.88M | -10.88M | -9.14M | -14.57M | -3.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -525.76% | -1,139.54% | -3,614.99% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -14.40M | -215.00K | 414.00K | 1.44M | 1.92M | 934.00K | 65.00K | 35.00K | 253.00K | 40.00K | -2.92M | -6.00K |
| Income Before Tax | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.78M | -12.30M | -16.85M | -10.62M | -9.10M | -17.48M | -3.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -479.93% | -1,133.55% | -3,607.49% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 705.00K | -519.00K | -1.16M | -1.92M | 75.00K | 12.36M | 106.00K | 21.24M | 1.00K | 1.00K | 6.00K |
| Net Income | -6.91M | -18.57M | -31.95M | -27.61M | -18.54M | -9.86M | -12.30M | -16.95M | -10.62M | -9.10M | -17.49M | -3.15M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -483.61% | -1,133.55% | -3,630.19% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -30.05 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| EPS Diluted | -29.95 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| Weighted Avg Shares Out | 230.00K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
| Weighted Avg Shares Out (Dil) | 230.79K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
Week In Review: Baidu Raising $2 Billion For New China Biopharma
Viking Therapeutics: Another Year In Review
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript
Inventiva SA Starts U.S. IPO Rollout
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC), LivaNova (LIVN) and Theratechnologies (THTX)
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), NuVasive (NUVA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Akero Therapeutics (AKRO), Shockwave Medical (SWAV) and VBI Vaccines (VBIV)
Source: https://incomestatements.info
Category: Stock Reports